ORGO Sales Drop 23%
Organogenesis (NASDAQ:ORGO), a regenerative medicine company specializing in advanced wound care and surgical and sports medicine products, reported Q2 2025 results on August 7, 2025. The standout news: GAAP revenue was $100.8 million for Q2 2025, missing analyst estimates of $103.4 million (GAAP). However, On a GAAP basis, earnings per share were $0.10 in Q2 2025, substantially exceeding expectations. The quarter showed steep declines in the core wound care business, with net product revenue from advanced Wound Care products decreasing 25% year-over-year, offset partially by strict cost management that resulted in a narrower GAAP net loss than last year. Overall, the quarter was marked by top-line weakness but clear progress in expense reduction and operational focus during a period of regulatory uncertainty.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Organogenesis focuses on developing and marketing advanced therapies to treat severe wounds and injuries. The company’s primary markets are advanced wound care -- which covers products like bioengineered skin tissues and wound matrices for difficult-to-heal wounds -- and surgical and sports medicine, which offers products used in surgery and joint injuries.
Source Fool.com
